The Mediterranean Institute for the Advance of Biotechnology and Health Research Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01329770
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

The Mediterranean Institute for the Advance of Biotechnology and Health Research | Yolanda de Diego Otero

Active Ingredients

Drugs in Phase 2 Trials (2)

vitamin c (2 trials)

vitamin e (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Fragile X Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2